EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market including revolutionary natural non-antibiotic antimicrobial products, today announced that the New York Stock Exchange has accepted NovaBay’s plan to regain compliance with the NYSE MKT’s continued listing standards. As previously disclosed, the NYSE notified the Company on April 28, 2015 that it had fall
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: U.S. Congress has passed a new bill called The Steve Gleason Act that improves the possibility for people with communication disabilities to receive public funding of speech-generating devices (SGDs) through Medicare. President Obama’s subsequent signing of the bill is expected to take place shortly. For Tobii Dynavox, which develops and sells both eye tracking and touchscreen-based assistive technology solutions, the new bill is likely to introduce
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced top-line results from its TIME-2 study of AKB-9778 in DME. The combination of AKB-9778 (dosed at 15 mg BID) and Lucentis® (ranibizumab injection) provided a clinically significant benefit in reduction of central subfield thickness (CST) compared to Lucentis® alone (p=0.008). In association with this improvement in CST, a positive trend also sh
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150. “The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced the first commercial implants of the Argus® II Retinal Prosthesis System (“Argus II”) have been performed in Austria and Turkey, and the first implant in Spain through a distribution agreement with IMEX has been performed. IMEX is the largest
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces top line results from investigator-sponsored Phase II study of Medidur for uveitis. Statistically significant reduction in recurrence of disease and visual acuity.
WASHINGTON–(BUSINESS WIRE)–Researchers have harnessed the human eye’s ability to detect subtle color differences and identify ‘thin films’ that differ in thickness by a few nanometers, about the width of a single virus.
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a revolutionary optical lens implant for treating presbyopia today announced that it has treated over 50% of subjects in the second stage enrollment of its pivotal study. Presbia received FDA approval to commence the second stage of its pivotal study in February, and continues enrollment of subjects at eleven investigational sites acros
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced data from its phase 1 safety study of X-82 at ISOPT.
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, to present July 10 at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/gbr5bg/north_america) has announced the addition of the “North America Ophthalmology Cataract Surgery Devices Market by Sub-Market (Intraocular Lenses, Phacoemuls…
ORLANDO, Fla. & CHENNAI, India–(BUSINESS WIRE)–The Intraocular Implant and Refractive Society of India (IIRSI) awarded a Special Gold Medal to Nicholas T. Curtis, CEO of LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, for his outstanding contribution to industry. The award was presented in Chennai at the IIRSI Conference by Dr. C. Vijaya Bhaskar, honorable Minister for Health, Medical Education and Family Welfare for the state of
ORLANDO, Fla. & DELHI, India–(BUSINESS WIRE)–Dr. Kamal Kapur Chooses LENSAR’s Advanced Femtosecond Cataract Platform To Launch Laser-Assisted Cataract Procedure Practice at Sharp Sight Centres in Delhi, India
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Roger Girard as Chief Strategy Officer. Having built 14 successful companies over the past 40 years in multiple industries, Girard brings deep experience in business management and will
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/5rfx92/retinitis) has announced the addition of the “Retinitis Pigmentosa (Retinitis)-API Insights” report to their offering. Retinitis Pigmentosa (Retinitis)-API…
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/wzsmx2/gene_therapy) has announced the addition of the “Gene Therapy Ophthalmology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscap…
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/hshg6b/retinal_vein) has announced the addition of the “Retinal Vein Occlusion – Pipeline Review, H1 2015” report to their offering. This report provides comprehe…
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Julie McHugh and Michael M. du Toit have been elected to the Company’s Board of Directors. Both individuals bring extensive senior healthcare-focused leadership experience, Ms. McHug
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/z46fl6/epicast_report) has announced the addition of the “EpiCast Report: Glaucoma – Epidemiology Forecast to 2023” report to their offering. Glaucoma is a common…
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, today anno…